Format

Send to

Choose Destination
Vaccine. 2016 Oct 26;34(45):5436-5441. doi: 10.1016/j.vaccine.2016.08.018. Epub 2016 Sep 1.

Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories.

Author information

1
Department of Virology, Institute of Experimental Medicine, 12 Acad. Pavlov Street, Saint Petersburg 197376, Russia. Electronic address: vaccine@mail.ru.
2
Vaccine Production, Serum Institute of India, 212/2 Hadapsar, Pune, India. Electronic address: leena.yeolekar@seruminstitute.com.
3
Department of Virology, Institute of Experimental Medicine, 12 Acad. Pavlov Street, Saint Petersburg 197376, Russia. Electronic address: irina.v.kiseleva@mail.ru.
4
Department of Virology, Institute of Experimental Medicine, 12 Acad. Pavlov Street, Saint Petersburg 197376, Russia. Electronic address: isakova.sivak@gmail.com.

Abstract

Influenza is a viral infection that affects much of the global population each year. Vaccination remains the most effective tool for preventing the disease. Live attenuated influenza vaccine (LAIV) has been used since the 1950s to protect humans against seasonal influenza. LAIVs developed by the Institute of Experimental Medicine (IEM), Saint Petersburg, Russia, have been successfully used in Russia since 1987. In 2006, the World Health Organization (WHO) announced a Global action plan for influenza vaccines (GAP). WHO, recognizing potential advantages of LAIV over the inactivated influenza vaccine in a pandemic situation, included LAIV in the GAP. BioDiem Ltd., a vaccine development company based in Melbourne, Australia which held the rights for the Russian LAIV, licensed this technology to WHO in 2009. WHO was permitted to grant sub-licenses to vaccine manufacturers in newly industrialized and developing countries to use the Russian LAIV for the development, manufacture, use and sale of pandemic and seasonal LAIVs. To date, WHO has granted sub-licenses to vaccine manufacturers in China (Changchun BCHT Biotechnology Co., Ltd.), India (Serum Institute of India Pvt. Ltd.) and Thailand (Government Pharmaceutical Organization). In parallel, in 2009, IEM signed an agreement with WHO, under which IEM committed to supply pandemic and seasonal candidate vaccine viruses to the sub-licensees. This paper describes the progress made by collaborators from China, India, Russia and Thailand in developing preventive measures, including LAIV against pandemic influenza.

KEYWORDS:

Clinical trials; Influenza; Live attenuated influenza vaccine; Pandemic preparedness; Potentially pandemic viruses; Preclinical studies; Seasonal vaccine; Technology transfer

PMID:
27593158
PMCID:
PMC5357706
DOI:
10.1016/j.vaccine.2016.08.018
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center